-
Mashup Score: 4
Background The randomized, double-blind, phase 3 ASPECT-NP trial evaluated the efficacy of 3 g of ceftolozane/tazobactam (C/T) versus 1 g of meropenem infused every 8 h for 8 to 14 days for treatment of adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). We assessed the probability of target attainment and compared efficacy outcomes from…
Source: Critical CareCategories: Critical Care, Latest HeadlinesTweet
-
Mashup Score: 2
Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites. Among nosocomial pneumonia subtypes, ventilated HABP (vHABP) is associated with the lowest survival. In the ASPECT-NP randomized, controlled trial, participants with vHABP treated with ceftolozane/tazobactam…
Source: Critical CareCategories: Critical Care, Latest HeadlinesTweet-
#CritCare #OA #Ceftolozane/#tazobactam vs #meropenem in #ventilated #hospital_acquired #bacterial_pneumonia https://t.co/IKp7GPwGHe #FOAMed #FOAMcc #BMC @ISICEM @jlvincen #ventilation #respiratory_failure https://t.co/GRKgIk4J2H
-
-
Mashup Score: 5Update of the treatment of nosocomial pneumonia in the ICU - 5 year(s) ago
In accordance with the recommendations of, amongst others, the Surviving Sepsis Campaign and the recently published European treatment guidelines for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), in the event of a patient with such infections, empirical antibiotic treatment must be appropriate and administered as early as possible. The aim of this manuscript is to…
Source: Critical CareCategories: Critical Care, Latest HeadlinesTweet-
#CritCare #OpenAccess https://t.co/TIXXXdHInR What’s new in treatment protocols of nosocomial #pneumonia #FOAMed #FOAMcc #BMC #ICU #Ceftazidime #Avibactam #Ceftolozane #Tazobactam #pseudomonas #PCR #KPC #vantilation #intubation @jlvincen @ISICEM https://t.co/KyBNySz4Cm
-
#CritCare #OA Insights in #nosocomial #pneumonia https://t.co/zyZxQP7s8z #FOAMed #FOAMcc #BMC @ISICEM @jlvincen #ICU #trial #bacteria #Pseudomonas_aeruginosa #resistance #Ceftolozane #tazobactam #renal_clearance https://t.co/4VwMgnBlua